Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2010Diabetes Obesity and Metabolism

Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study

View Full Paper
Ask AI
Bookmark
Share

Authors

David R. Matthews
David R. MatthewsChurchill HospitalSDS. DejagerLaboratoire Matériaux et Durabilité des ConstructionsBÅBo ÅhrénLinköping University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Matthews et al. (2010) studied this question.

synapsesocial.com/papers/6a716e17fe4101aa97e09154https://doi.org/10.1111/j.1463-1326.2010.01233.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose2007 · 131 citations
  2. 2Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy2009 · 75 citations
  3. 3Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year2005 · 308 citations
  4. 4Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy2008 · 299 citations
  5. 5Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes2009 · 184 citations